@article{3156734,
    title = "Treatment of canine leishmaniosis with aminosidine at an optimized
dosage regimen: A pilot open clinical trial",
    author = "Athanasiou, L. V. and Saridomichelakis, M. N. and Kontos, V. I. and and Spanakos, G. and Rallis, T. S.",
    journal = "Veterinary Parasitology",
    year = "2013",
    volume = "192",
    number = "1-3",
    pages = "91-97",
    publisher = "ELSEVIER SCIENCE BV",
    issn = "0304-4017",
    doi = "10.1016/j.vetpar.2012.10.011",
    keywords = "Leishmania; Dog; Aminosidine; Efficacy; Dosage",
    abstract = "Leishmaniosis due to Leishmania infantum (Syn: L. chagasi) is one of the
most common diseases of dogs in Mediterranean countries and also has
zoonotic potential. The aim of this study was to evaluate the efficacy
of an optimized dosage regimen of aminosidine for the treatment of
canine leishmaniosis (CanL) in terms of clinical remission, restoration
of clinicopathological abnormalities, evolution of antibody titer, lymph
node and bone marrow parasitic density and of PCR-based parasitological
cure. Twelve non-uremic dogs without proteinuria, presenting clinical
signs of CanL were included in the study. The diagnosis was confirmed by
serology, microscopy and PCR of lymph node and bone marrow samples.
Aminosidine was administered subcutaneously at the dose of 15 mg/kg body
weight, once daily, for 21 consecutive days. A partial remission of the
clinical signs, amelioration of clinicopathological abnormalities such
as anemia, lymphopenia, hyperproteinemia, hyperglobulinemia, and reduced
albumin/globulin ratio and reduced lymph node and bone marrow parasitic
density were witnessed, although parasitological cure was not achieved.
Since data are not supportive enough for the use of aminosidine as an
alternative treatment, a large-scale controlled clinical trial using
this optimized dosage regimen of aminosidine is warranted to compare
efficacy against currently used drugs. (c) 2012 Elsevier B.V. All rights
reserved."
}